RIZZOLI, Vittorio
 Distribuzione geografica
Continente #
AS - Asia 6.456
NA - Nord America 6.379
EU - Europa 4.209
SA - Sud America 772
AF - Africa 304
Continente sconosciuto - Info sul continente non disponibili 17
OC - Oceania 2
Totale 18.139
Nazione #
US - Stati Uniti d'America 6.180
SG - Singapore 2.361
CN - Cina 2.000
VN - Vietnam 963
IE - Irlanda 763
FI - Finlandia 741
SE - Svezia 739
BR - Brasile 598
UA - Ucraina 564
DE - Germania 550
HK - Hong Kong 437
TR - Turchia 271
FR - Francia 200
ZA - Sudafrica 200
NL - Olanda 183
CA - Canada 138
IT - Italia 137
GB - Regno Unito 112
IN - India 90
AR - Argentina 69
BD - Bangladesh 57
RU - Federazione Russa 51
CI - Costa d'Avorio 42
EC - Ecuador 38
MX - Messico 38
IQ - Iraq 33
JP - Giappone 32
BE - Belgio 31
RO - Romania 25
PH - Filippine 23
PL - Polonia 23
ID - Indonesia 22
IR - Iran 22
ES - Italia 18
PK - Pakistan 18
CO - Colombia 17
TH - Thailandia 17
TW - Taiwan 17
MA - Marocco 16
CZ - Repubblica Ceca 15
EU - Europa 15
UZ - Uzbekistan 14
LT - Lituania 13
UY - Uruguay 12
SA - Arabia Saudita 10
AT - Austria 9
CL - Cile 9
PY - Paraguay 9
VE - Venezuela 9
AE - Emirati Arabi Uniti 8
JO - Giordania 8
KR - Corea 8
PE - Perù 8
EG - Egitto 7
KE - Kenya 7
LV - Lettonia 7
DO - Repubblica Dominicana 6
MY - Malesia 6
TN - Tunisia 6
AL - Albania 5
AZ - Azerbaigian 5
DZ - Algeria 5
ET - Etiopia 5
KZ - Kazakistan 5
NP - Nepal 5
IL - Israele 4
JM - Giamaica 4
NG - Nigeria 4
SK - Slovacchia (Repubblica Slovacca) 4
CR - Costa Rica 3
LK - Sri Lanka 3
OM - Oman 3
SN - Senegal 3
AO - Angola 2
BB - Barbados 2
BG - Bulgaria 2
BO - Bolivia 2
CH - Svizzera 2
GE - Georgia 2
GR - Grecia 2
HN - Honduras 2
HU - Ungheria 2
KG - Kirghizistan 2
LB - Libano 2
LU - Lussemburgo 2
MD - Moldavia 2
NI - Nicaragua 2
PS - Palestinian Territory 2
RS - Serbia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AU - Australia 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CM - Camerun 1
CU - Cuba 1
CY - Cipro 1
DK - Danimarca 1
GA - Gabon 1
Totale 18.124
Città #
Singapore 1.153
Dublin 762
Chandler 711
Ashburn 695
Jacksonville 654
San Jose 516
Beijing 450
Hong Kong 403
Santa Clara 373
Ho Chi Minh City 279
Dearborn 253
Nanjing 238
Izmir 227
Boardman 224
Hanoi 211
Dallas 208
Johannesburg 191
San Mateo 186
Princeton 160
Los Angeles 148
Ann Arbor 141
Lauterbourg 141
Toronto 105
Shanghai 103
Wilmington 98
Shenyang 88
Nanchang 82
Helsinki 76
Kunming 74
Hefei 73
Munich 70
New York 69
Hebei 65
Düsseldorf 63
Jinan 63
São Paulo 56
Buffalo 53
Parma 50
Des Moines 49
Da Nang 47
Haiphong 45
Abidjan 42
Woodbridge 40
Changsha 39
Marseille 38
Guangzhou 37
Tianjin 37
Jiaxing 35
Bremen 33
Moscow 33
Brussels 31
Columbus 31
Pune 30
Seattle 28
Kocaeli 26
Leawood 25
Stockholm 24
Turku 24
Zhengzhou 24
Tokyo 23
Frankfurt am Main 22
Grafing 22
Warsaw 22
Hải Dương 21
Atlanta 20
Hangzhou 20
Augusta 19
Norwalk 19
Brooklyn 18
Houston 18
Montreal 18
Council Bluffs 17
Ningbo 16
Amsterdam 15
Focsani 15
London 15
Rio de Janeiro 15
Mestre 14
Phoenix 14
San Francisco 14
Lanzhou 13
Monmouth Junction 13
Nuremberg 13
Orem 13
Tashkent 13
Ardabil 12
Bologna 12
Boston 12
Chongqing 12
Denver 12
Fremont 12
Guayaquil 12
Haikou 12
Thái Nguyên 12
Biên Hòa 11
Chicago 11
Quito 11
Taizhou 11
The Dalles 11
Baghdad 10
Totale 10.845
Nome #
Are the Myeloma bone microevironment cells tumoral or not? 222
Diabetes impairs hematopoietic stem cell mobilization by altering niche function 215
Angiopoietin-1 and Osteopontin Expression by CD138+ Myeloma Cells Rather Than VEGF and CD45 Correlates with Bone Marrow Angiogenesis in Multiple Myeloma Patients at the Diagnosis 209
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 184
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 182
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 180
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 179
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia 177
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 177
The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment 176
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 175
Chemokine receptors CXCR3 and CXCR4 expression in B cell and plasma cell malignancy 170
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 167
Angiopoietin-1 and osteopontin expression by CD138+myeloma cells rather than VEGF and CD45 correlates with bone marrow angiogenesis in Multiple Myeloma patients at the diagnosis. 167
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 164
Amifostine (WR-2721) selective protection against melphalan genotoxicity 163
Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. 160
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 158
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 157
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 155
A translocation t(4;13)(q21;q14) as single clonal chromosomal abnormality in a parathyroid adenoma 155
Angiopoietins expression by human myeloma cells 154
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 154
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 151
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 150
Angiogenic switch in multiple myeloma patients 149
Autologous bone marrow transplantation in acute myeloid leukemia: a single center experience 148
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. 147
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 147
Angiogenic properties of human myeloma cells: role of angiopoietin system 146
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 145
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 144
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 144
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 144
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 143
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 141
Ectopic production of osteopontin by human myeloma cells and its involvement in myeloma induced angiogenesis 140
Analysis of lineage involvment in Philadelphia chromosome positive acute lymphoblastic leukaemia 139
Bleomycin Genotoxicity and Amifostine (WR-2721) Cell Protection in Normal Leukocytes versus K562 Tumoral Cells 139
Do human myeloma cells directly produce basic FGF? 139
Alterations of microenvironment in multiple myeloma patients: Interactions between myeloma cells and osteoprogenitor cells 139
Angiopoietin-1 and myeloma-induced angiogenesis 137
The new tumor suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro-angiogenic molecules by myeloma cells and suppresses hypoxia inducible factor (HIF)-1{alpha} activity being involved in myeloma-induced angiogenesis. 137
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis 135
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: potential relationship with myeloma-induced angiogenesis 134
A distintive nuclear morfology in three cases of acute myeloid leukaemia associated with loss HLA-DR expression and FTL3 internal tandem duplication 133
EPIRUBICIN PLUS G-CSF ELICITED PERIPHERAL BLOOD PROGENITOR CELL MOBILIZATION IS SIGNIFICANTLY ENHANCED BY AMIFOSTINE 132
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment 132
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients 132
Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation. 129
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 127
Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation. 127
Expression and role of chemokine receptor CXCR3 in multiple myeloma 127
Angiogenic switch in multiple myeloma 126
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation 125
Autotransplantation in acute leukemia. 125
Assessment of the efficacy of a last-generation polyvalent immunoglobulin in the treatment of idiopathic thrombocytopenic purpura. 124
Macrophage inflammatory protein (MIP)-3 alpha/CCL20 and its receptor CCR6 are overexpressed in the bone microenvironment and involved in osteoclast formation in multiple myeloma patients. 123
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent anti-tumor activity in vivo against human multiple myeloma xenograft model. 123
Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets 122
DKK-1 and sFRP-3 expression by myeloma cell and bone marrow plasma levels in multiple myeloma and MGUS patients: Potential relationship with bone status. 121
Gamma-rays from Mössbauer sources: a low-dose approach to cancer therapy 120
RANKL is critically involved in the physiopathology of multiple myeloma 119
Arsenic trioxide in hematological malignancies: The new discovery of an ancient drug 118
BCL2 oncogene protein expression in human hematopoietic precursors during fetal life. 117
Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated marrow. 117
Mossbauer analysis of bone marrow before and after purging with Asta-z 7557 116
p29ING4 regulates the production of pro-angiogenic molecules by human myeloma cells in normoxic and hypoxic conditions being involved in myeloma-induced angiogenesis. 116
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 115
Osteopontin is produced by human multiple myeloma cells 115
Pan-aurora kinase inhibitor MK-0457 synergistically potentiates Apo2l/TRAIL cytotoxicity in Multiple Mieloma cells sensitive and resistant to bortezomib 115
Beta-catenin depended and independent effects induced by myeloma cells in human and murine osteoblasts and osteoblast progenitors. 114
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease 114
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple Myeloma bone disease 113
Effects of Mössbauer radiation on bone marrow cultures 112
DNA damage by tobacco smoke and some antiblastic drugs evaluated using the Comet assay 110
Down-modulation of ERK protein kinase activity suppresses human myeloma cell proliferation and myeloma-induced angiogenesis by VEGF inhibition 110
Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens 108
VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group 107
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting 107
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 106
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 106
Multiple myeloma patient with unusual extramedullary involvement 106
Impact of XIAP protein levels on the survival of myeloma cells 105
The proteasome inhibitor bortezomib affects osteoblastogenesis and bone formation in vitro and in vivo in multiple myeloma patients. 105
HUMAN MYELOMA CELLS EXPRESS THE BONE REGULATING GENE RUNX2/CBFA1 AND PRODUCE OSTEOPONTIN THAT IT IS INVOLVED IN MYELOMA INDUCED ANGIOGENESIS 103
IL-7 is produced by myeloma cells in presence of IL-6 101
Human myeloma cells produce angiopoietin-1: potential relationship with myeloma-induced angiogenesis 100
MYELOMA CELLS BLOCK RUNX2/CBFA1 ACTIVITY IN HUMAN BONE MARROW OSTEOBLAST PROGENITORS AND INHIBIT OSTEOBLAST FORMATION AND DIFFERENTIATION 99
Role of tumor necrosis factor-related activation-induced cytokine (TRANCE) in multiple myeloma 99
Human myeloma cells express IL-7 mRNA and secrete IL-7 in presence of IL-6 99
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 99
Purging the bone marrow in non-Hodgkin's lymphomas. Is there any evidence of its value? 99
Evaluation of amifostine (WR-271) cytoprotection against in vitro bleomycin-induced clastogenicity in human leukocytes by SCGE assay 98
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide 98
Expression of pro-angiogenetic factors by myeloma cells: role of the angiopoietin system 96
The proteasome inhibitor bortezomib stimulates the osteogenic differentiation of mesenchymal cells in vitro and may increase osteoblast formation in vivo in multiple myeloma patients. 96
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells 96
Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients 96
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients 96
Totale 13.332
Categoria #
all - tutte 59.688
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.688


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021320 0 0 0 0 0 0 0 0 0 37 254 29
2021/2022784 11 2 5 56 16 31 94 137 35 85 80 232
2022/20232.743 357 295 171 193 250 284 53 151 891 11 74 13
2023/2024866 40 105 21 16 75 196 82 89 22 41 69 110
2024/20252.899 52 178 198 202 313 284 47 93 419 283 242 588
2025/20266.186 576 589 763 665 1.006 402 688 208 904 385 0 0
Totale 18.235